论文部分内容阅读
宫颈癌是女性生殖系统恶性肿瘤的主要死因。根据美国国家生化学会发布的指南,目前可能存在临床价值的宫颈癌血清肿瘤标志物有鳞状细胞癌抗原(SCC-Ag)、糖类抗原125(CA125)、癌胚抗原(CEA)和角蛋白家族成员[组织多肽抗原(TPA)、组织多肽特异抗原(TPS)、细胞角蛋白21-1(Cyfra21-1)]。目前掌握的临床及科研资料显示,SCC-Ag是宫颈鳞癌唯一具有临床价值的血清标志物,而CA125和CEA作为宫颈腺癌的临床检测指标有继续研究的价值。“,”Cancer of the uterine cervix is a major cause of death from gynecologic cancer worldwide. According to the guidelines of NACB,tumor markers that may be helpful in the management of patients with cervical cancer are:squamous cell carcinoma antigen(SCC-Ag),Carbohydrate antigen (CA)125,carcinoem-bryonic antigen ( CEA ) , tissue polypeptide antigen ( TPA ) , tissue polypeptide specific antigen ( TPS ) , and Cyfra21-1. For squamous cell cervical cancer,SCC-Ag is the only serum marker of clinical value. CEA and CA125 in particular have demonstrated possible utility in patients with cervical adenocarcinoma.